AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Beam Therapeutics Inc. (BEAM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

33.17

-0.92 (-2.70%)

At close: Feb 20, 2025, 3:59 PM

33.20

0.08%

After-hours: Feb 20, 2025, 05:33 PM EST

undefined% (undefined)

Bid	32.55
Market Cap	2.75B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.58
PE Ratio (ttm)	-21
Forward PE	n/a
Analyst	Buy

Ask	34.55
Volume	1,031,129
Avg. Volume (20D)	1,169,286
Open	34.36
Previous Close	34.09
Day's Range	32.92 - 34.71
52-Week Range	20.84 - 49.50
Beta	undefined

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 6, 2020

Employees 472

Stock Exchange NASDAQ

Ticker Symbol BEAM

Website https://www.beamtx.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 44.69% from the latest price.

Buy 54.55%

Hold 36.36%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Beam Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+5.49%

Beam Therapeutics shares are trading higher. The c... Unlock content with Pro Subscription

3 months ago

+11.24%

Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.

News

1 week ago · zacks.com

Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

1 week ago · zacks.com

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

3 weeks ago · zacks.com

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

4 weeks ago · zacks.com

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.

1 month ago · zacks.com

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 month ago · schaeffersresearch.com

2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy

Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cu...

2 months ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

2 months ago · zacks.com

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19.

2 months ago · zacks.com

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?